Oral anticoagulant drugs

New England Journal of Medicine

Volumn 324, Issue 26, 1991, Pages 1865-1875

  Oates, John A ^a   Wood, Alastair J J ^a   Hirsh, Jack ^b  

^a Hamilton Civic Hospitals Research Centre ^*

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

FEMALE; HUMAN; ORAL DRUG ADMINISTRATION; PREGNANCY; REVIEW;

ADMINISTRATION, ORAL; ANTICOAGULANTS; FEMALE; HUMAN; PREGNANCY; SUPPORT, NON-U.S. GOV'T; WARFARIN;

EID: 0026432629     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199106273242606     Document Type: Review

References (133)

1. Deykin D. Warfarin therapy. N Engl J Med 1970; 283:691-694
2. Deykin. Warfarin therapy. N Engl J Med 1970; 283:801-803
3. Kirkwood T.B.L. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 1983; 49:238-244
4. Hirsh J., Poller L., Deykin D., Levine M., Dalen J.E. Optimal therapeutic range for oral anticoagulants. Chest 1989; 95:Suppl 2:5S-11S.
5. Erratum, Chest 1989; 96:962.
6. Breckenridge A.M. Oral anticoagulant drugs: pharmacokinetic aspects. Semin Hematol 1978; 15:19-26.
7. O#x0027;Reilly R.A. Vitamin K and other oral anticoagulant drugs. Annu Rev Med 1976; 27:245-261
8. Furie B., Furie B.C. Molecular basis of vitamin K-dependent γ-carboxylation. Blood 1990; 75:1753-1762
9. Whitlon D.S., Sadowski J.A., Suttie J.W. Mechanisms of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 1978; 17:1371-1377
10. Fasco M.J., Hildebrandt E.F., Suttie J.W. Evidence that warfarin anticoagulant action involves two distinct reductase activities. J Biol Chem 1982; 257:11210-2.
11. Choonara I.A., Malia R.G., Haynes B.P., et al. The relationship between inhibition of vitamin Kl 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol 1988; 25:1-7.
12. Trivedi L.S., Rhee M., Galvan J.H., Fasco M.J. Normal and warfarin-resistant rat hepatocyte metabolism of vitamin K 2,3 epoxide: evidence for multiple pathways of hydroxyvitamin K formation. Arch Biochem Biophys 1988; 264:67-73.
13. Stenflo J., Fernlund P., Egan W., Roepstorff P. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci USA 1974; 71:2730-2733
14. Nelsestuen G.L., Zytkovicz T.H., Howard J.B. The mode of action of vitamin K: identification of γ-carboxyglutamic acid as a component of prothrombin. J Biol Chem 1974; 249:6347-6350
15. Nelsestuen G.L. Role of gamma-carboxyglutamic acid: an unusual protein transition required for calcium-dependent binding of prothrombin to phospholipid. J Biol Chem 1976; 251:5648-5656
16. Prendergast F.G., Mann K.G. Differentiation of metal ion-induced transitions of prothrombin fragment 1. J Biol Chem 1977; 252:840-850
17. Borowski M., Furie B.C., Bauminger S., Furie B. Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipid. J Biol Chem 1986; 261:14969-75.
18. Friedman P.A., Rosenberg R.D., Hauschka P.V., Fitz-James A. A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients. Biochim Biophys Acta 1977; 494:271-276
19. Malhotra O.P., Nesheim M.E., Mann K.G. The kinetics of activation of normal and gamma-carboxyglutamic acid-deficient prothrombins. J Biol Chem 1985; 260:279-287
20. Malhotra O.P. Dicoumarol-induced prothrombins containing 6, 7, and 8 γ-carboxyglutamic acid residues: isolation and characterization. Biochem Cell Biol 1989; 67:411-421
21. Malhotra. Dicoumarol induced 9-gamma carboxy glutamic acid prothrombin: isolation and comparison with 6-, 7-, 8-, and 10-gamma carboxy glutamic acid isomers. Biochemistry (in press).
22. Kelly J.G., O#x0027;Malley K. Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinet 1979; 4:1-15.
23. O#x0027;Reilly R.A. Warfarin metabolism and drug-drug interactions. In: Wessler S, Becker CG, Nemerson Y, eds. The new dimensions of warfarin prophylaxis. Vol. 214 of Advances in experimental medicine and biology. New York: Plenum, 1986: 205-12.
24. Sutcliffe F.A., MacNicoll A.D., Gibson G.G. Aspects of anticoagulant action: a review of the pharmacology, metabolism and toxicology of warfarin and congeners. Rev Drug Metabol Drug Interact 1987; 5:225-272
25. O#x0027;Reilly R.A., Aggeler P.M. Determinants of the response to oral anticoagulant drugs in man. Pharmacol Rev 1970; 22:35-96.
26. O#x0027;Reilly R.A., Pool J.G., Aggeler P.M. Hereditary resistance to coumarin anticoagulant drugs in man and rat. Ann N Y Acad Sci 1968; 151:913-931
27. O#x0027;Reilly R.A., Aggeler P.M., Hoag M.S., Leong L.S., Kropatkin M.L. Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs: the first reported kindred. N Engl J Med 1964; 271:809-815
28. Alving B.M., Strickler M.P., Knight R.D., Barr C.F., Berenberg J.L., Peck C.C. Hereditary warfarin resistance. Arch Intern Med 1985; 145:499-501.
29. O#x0027;Reilly R.A., Rytand D.A. “Resistance” to warfarin due to unrecognized vitamin K supplementation. N Engl J Med 1980; 303:160-161
30. Suttie J.W., Mummah-Schendel L.L., Shah D.V., Lyle B.J., Greger J.L. Vitamin K deficiency from dietary vitamin K restriction in humans. Am J Clin Nutr 1988; 47:475-480
31. Lader E., Yang L., Clarke A. Warfarin dosage and vitamin K in Osmolite. Ann Intern Med 1980; 93:373-374
32. Bell R.G. Metabolism of vitamin K and prothrombin synthesis: anticoagulants and the vitamin K-epoxide cycle. Fed Proc 1978; 37:2599-2604
33. Richards R.K. Influence of fever upon the action of 3,3′-methylene bis-(4-hydroxy-coumarin) (Dicumarol). Science 1943; 97:313.
34. Owens J.C., Neely W.B., Owen W.R. Effect of sodium dextrothyroxine in patients receiving anticoagulants. N Engl J Med 1962; 266:76-79
35. Loeliger E.A., van der Esch B., Mattern M.J., Hemker H.C. The biological disappearance rate of prothrombin, factors VII, IX and X from plasma in hypothyroidism, hyperthyroidism, and during fever. Thromb Diath Haemorrh 1964; 10:267-277
36. Koch-Weser J., Sellers E.M. Drug interactions with coumarin anticoagulants. N Engl J Med 1971; 285:487-498
37. Koch-Weser. Drug interactions with coumarin anticoagulants. N Engl J Med 1971; 285:547-558
38. Breckenridge A., Orme M., Wesseling H., Lewis R.J., Gibbons R. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974; 15:424-430
39. O#x0027;Reilly R.A. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 1974; 16:348-354
40. O#x0027;Reilly R.A., Trager W.F. Stereoselective interaction of phenylbutazone with l3C/12C-labeled racemates of warfarin in man. Fed Proc 1978; 37:545. abstract.
41. Lewis R.J., Trager W.F., Chan K.K., et al. Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest 1974; 53:1607-1617
42. Toon S., Low L.K., Gibaldi M., et al. The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther 1986; 39:15-24.
43. O#x0027;Reilly R.A. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 1976; 295:354-357
44. O#x0027;Reilly. Stereoselective interaction of trimethoprim–sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med 1980; 302:33-35
45. Toon S., Hopkins K.J., Garstang F.M., Diquet B., Gill T.S., Rowland M. The warfarin-cimetidine interaction: stereochemical considerations. Br J Clin Pharmacol 1986; 21:245-246
46. Choonara I.A., Cholerton S., Haynes B.P., Breckenridge A.M., Park B.K. Stereoselective interaction between the R enantiomer of warfarin and cimetidine. Br J Clin Pharmacol 1986; 21:271-277
47. Sutfin T., Balmer K., Bostrom H., Eriksson S., Hoglund P., Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11:176-184
48. O#x0027;Reilly R.A., Trager W.F., Rettie A.E., Goulart D.A. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther 1987; 42:290-294
49. O#x0027;Reilly R.A., Trager W.F., Motley C.H., Howard W. Interaction of secobarbital with warfarin pseudoracemates. Clin Pharmacol Ther 1980; 28:187-195
50. O#x0027;Reilly R.A. Interaction of chronic daily warfarin therapy and rifampin. Ann Intern Med 1975; 83:506-508
51. Denbow C.E., Fraser H.S. Clinically significant hemorrhage due to warfarin-carbamazepine interaction. South Med J 1990; 83:981.
52. O#x0027;Reilly R.A. Lack of effect of fortified wine ingested during fasting and anticoagulant therapy. Arch Intern Med 1981; 141:458-459
53. Bechtold H., Andrassy K., Jahnchen E., et al. Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methyl-thiotetrazole cephalosporins. Thromb Haemost 1984; 51:358-361
54. O#x0027;Reilly R.A., Sahud M.A., Robinson A.J. Studies on the interaction of warfarin and clofibrate in man. Thromb Diath Haemorrh 1972; 27:309-318
55. Roth G.J., Majerus P.W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a paniculate fraction protein. J Clin Invest 1975; 56:624-632
56. Schulman S., Henriksson K. Interaction of ibuprofen and warfarin on primary haemostasis. Br J Rheumatol 1989; 38:46-49
57. Casenave J.-P., Packham M.A., Guccione M.A., Mustard J.F. Effects of penicillin G on platelet aggregation, release, and adherence to collagen. Proc Soc Exp Biol Med 1973; 142:159-166
58. Brown C.H. III, Natelson E.A., Bradshaw M.W., Williams T.W. Jr., Alfrey C.P. Jr. The hemostatic defect produced by carbenicillin. N Engl J Med 1974; 291:265-270
59. Weitekamp M., Aber R. Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA 1983; 249:69-71.
60. Graham D.Y., Smith J.L. Aspirin and the stomach. Ann Intern Med 1986; 104:390-398
61. Dale J., Myhre E., Loew D. Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. Am Heart J 1980; 99:746-752
62. Chesebro J.H., Fuster V., Elveback L.R., et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983; 51:1537-1541
63. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-360
64. Weibert R.T., Lorentz S.M., Townsend R.J., Cook C.E., Klauber M.F., Jagger P.I. Effect of erythromycin in patients receiving long-term warfarin therapy. Clin Pharm 1989; 8:210-214
65. Lorentz S.M., Weibert R.T. Potentiation of warfarin anticoagulation by topical testosterone ointment. Clin Pharm 1985; 4:332-334
66. Udall J.A. Human sources and absorption of vitamin K in relation to anticoagulation stability. JAMA 1965; 194:127-129
67. Quick A.J. The prothrombin time in haemophilia and in obstructive jaundice. J Biol Chem 1935; 109:73-74
68. Loeliger E.A., van den Besselaar A.M.H.P., Lewis S.M. Reliability and clinical impact of the normalization of the prothrombin times in oral anticoagulant control. Thromb Haemost 1985; 53:148-154
69. Loeliger E.A., van den Besselaar A.M.H.P., Broekmans A.W. Intensity of oral anticoagulation in patients monitored with various thromboplastins. N Engl J Med 1983; 308:1228-1229
70. Zucker S., Cathey M.H., Sox P.J., Hall E.C. Standardization of laboratory tests for controlling anticoagulant therapy. Am J Clin Pathol 1970; 53:348-354
71. Poller L. Progress in standardisation in anticoagulant control. Hematol Rev 1987; 1:225-241
72. Poller L., Thomson J.M. The interpretation of prothrombin results: a national survey. Br J Haematol 1969; 16:31-37
73. Poller L. Laboratory control of oral anticoagulants. BMJ 1987; 294:1184.
74. International Committee for Standardization in Haematology, International Committee on Thrombosis and Haemostasis. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Haemost 1985; 53:155-156
75. Wright I.S. Recent developments in antithrombotic therapy. Ann Intern Med 1969; 71:823-831
76. Poller L., Taberner D.A. Dosage and control of oral anticoagulants: an international collaborative survey. Br J Haematol 1982; 51:479-485
77. Poller L. Therapeutic ranges in anticoagulant administration. BMJ 1985; 290:1683-1686
78. Loeliger E.A., Poller L., Samama M., et al. Questions and answers on prothrombin time standardisation in oral anticoagulant control. Thromb Haemost 1985; 54:515-517
79. Poller L., Thomson J.M., Taberner D.A. Effect of automation on the prothrombin time test in NEQAS surveys. J Clin Pathol 1989; 42:97-100.
80. Hellemans J., Vorlat M., Verstraete M. Survival time of prothrombin and factors VII, IX and X after completely synthesis blocking doses of coumarin derivatives. Br J Haematol 1963; 9:506-512
81. Vigano S., Mannucci P.M., Solinas S., Bottasso B., Mariani G. Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br J Haematol 1984; 57:213-220
82. Thomas P., Fennerty A., Backhouse G., Bentley D.P., Campbell I.A., Routledge P.A. Monitoring effects of oral anticoagulants during treatment with heparin. BMJ 1984; 288:191.
83. Fennerty A., Dolben J., Thomas P., et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. BMJ 1984; 288:1268-1270
84. Francis C.W., Marder V.J., Evarts C.M., Yaukoolbodi S. Two-step warfarin therapy: prevention of postoperative venous thrombosis without excessive bleeding. JAMA 1983; 249:374-378
85. Powers P.J., Gent M., Jay R.M., et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med 1989; 149:771-774
86. Taberner D.A., Poller L., Burslem R.W., Jones J.B. Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. BMJ 1978; 1:272-274
87. Poller L., McKernan A., Thomson J.M., Elstein M., Hirsch P.J., Jones J.B. Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. BMJ 1987; 295:1309-1312
88. Hull R., Hirsh J., Jay R., et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307:1676-1681
89. Resnekov L., Chediak J., Hirsh J., Lewis H.D. Jr. Antithrombotic agents in coronary artery disease. Chest 1989; 95:Suppl 2:52S-72S.
90. Goldberg R.J., Gore J.M., Dalen J.E., Alpert J.S. Long-term anticoagulant therapy after acute myocardial infarction. Am Heart J 1985; 109:616-622
91. Assessment of short-term anticoagulant administration after cardiac infarction: report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council. BMJ 1969; 1:335-342
92. Anticoagulants in acute myocardial infarction: results of cooperative clinical trial. JAMA 1973; 225:724-729
93. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction: report of the Sixty Plus Reinfarction Study Research Group. Lancet 1980; 2:989-994
94. Smith P., Arnesen H., Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323:147-152
95. Kretschmer G., Wenzl E., Schemper M., et al. Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery. Lancet 1988; 1:797-798
96. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323:1505-1511
97. Turpie A.G.G., Gunstensen J., Hirsh J., Nelson H., Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988; 1:1242-1245
98. Saour J.N., Sieck J.O., Mamo L.A.R., Gallus A.S. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322:428-432
99. Hull R., Delmore T., Genton E., et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301:855-858
100. Hull R., Delmore T., Carter C., et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306:189-194
101. Lagerstedt C.I., Olsson C.-G., Fagher B.O., Öqvist B.W., Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 2:515-518
102. The EPSIM Research Group. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982; 307:701-708
103. Mok C.K., Boey J., Wang R., et al. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective clinical trial. Circulation 1985; 72:1059-1063
104. Petersen P., Boysen G., Godtfredsen J., Andersen E.D., Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989; 1:175-179
105. Stroke Prevention in Atrial Fibrillation Study Group Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med 1990; 322:863-868
106. Sevitt S., Gallagher N.G. Prevention of venous thrombosis and pulmonary embolism in injured patients: a trial of anticoagulant prophylaxis with phenindione in middle-aged and elderly patients with fractured necks of femur. Lancet 1959; 2:981-989
107. Leizorovicz A., Boissel J.P. Oral anticoagulant in patients surviving myocardial infarction. Eur J Clin Pharmacol 1983; 24:333-336
108. Sherman D.G., Dyken M.L., Fisher M., Harrison M.J.G., Hart R.G. Antithrombotic therapy for cerebrovascular disorders. Chest 1989; 95:Suppl 2:140S-155S.
109. Landefeld C.S., Rosenblatt M.W., Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med 1989; 87:153-159
110. Landefeld C.S., Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87:144-152
111. Levine M.N., Raskob G., Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest 1989; 95:Suppl 2:26S-36S.
112. Verhagen H. Local hemorrhage and necrosis of the skin and underlying tissues at starting therapy with dicumarol or dicumacyl. Acta Med Scand 1954; 148:455-467
113. Weinberg AC, Lieskovsky G., McGehee W.G., Skinner D.G. Warfarin necrosis of the skin and subcutaneous tissue of the male genitalia. J Urol 1983; 130:352-354
114. Broekmans A.W., Bertina R.M., Loeliger E.A., Hofmann V., Klingemann H.G. Protein C and development of skin necrosis during anticoagulant therapy. Thromb Haemost 1983; 49:251.
115. Zauber N.P., Stark M.W. Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. Ann Intern Med 1986; 104:659-660
116. Samama M., Horellou M.H., Soria J., Conard J., Nicolas G. Successful progressive anticoagulation in a severe protein C deficiency and previous skin necrosis at the initiation of oral anticoagulation treatment. Thromb Haemost 1984; 51:132-133
117. Grimaudo V., Gueissaz F., Hauert J., Sarraj A., Kruithof E.K.O., Bachmann F. Necrosis of skin induced by coumarin in a patient deficient in protein S. BMJ 1989; 298:233-234
118. Hall J.G., Pauli R.M., Wilson K.M. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980; 68:122-140
119. Ginsberg J.S., Hirsh J. Use of anticoagulants during pregnancy. Chest 1989; 95:Suppl 2:156S-160S.
120. Iturbe-Alessio I., del Carmen Fonseca M., Mutchinik O., Santos M.A., Zajarías A., Salazar E. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 1986; 315:1390-1393
121. McKenna R., Cale E.R., Vasan U. Is warfarin sodium contraindicated in the lactating mother? J Pediatr 1983; 103:325-327
122. Lao T.T., DeSwiet M., Letsky E., Walters B.J.N. Prophylaxis of thromboembolism in pregnancy: an alternative. Br J Obstet Gynaecol 1985; 92:202-206
123. Lucas F.V., Duncan A., Jay R.M., et al. A novel whole blood capillary technique for measuring the prothrombin time. Am J Clin Pathol 1987; 88:442-446
124. White R.H., McCurdy S.A., von Marensdorff H., Woodruff D.E. Jr., Leftgoff L. Home prothrombin time monitoring after the initiation of warfarin therapy: a randomized prospective study. Ann Intern Med 1989; 111:730-737
125. Blanchard R., Furie B.C., Kruger S.F., Waneck G., Jorgensen M.J., Furie B. Immunoassays of human prothrombin species which correlate with functional coagulant activities. J Lab Clin Med 1983; 101:242-255
126. Furie B., Diuguid C.F., Jacobs M., Diuguid D.L., Furie B.C. Randomized prospective trial comparing the active prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy. Blood 1990; 75:344-349
127. Church W.R., Bhushan F.H., Mann K.G., Bovill E.G. Discrimination of normal and abnormal prothrombin and protein C in plasma using a calcium ion-inhibited monoclonal antibody to a common epitope on several vitamin K-dependent proteins. Blood 1989; 74:2418-2425
128. Furie B., Furie B.C. Conformation-specific antibodies as probes of the gamma-carboxyglutamic acid-rich region of bovine prothrombin. J Biol Chem 1979; 254:9766-9771
129. Bauer K.A., Goodman T.L., Kass B.L., Rosenberg R.D. Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. J Clin Invest 1985; 76:826-836
130. Bauer K.A., Rosenberg R.D. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70:343-350
131. Hurstings M., Greenberg C., Parker J., et al. Clinical performance of a quantitative ELISA for prothrombin fragment 1.2. Blood 1989; 74:Suppl 1:256a. abstract.
132. Bern M.M., Lokich J.J., Wallach S.R., et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 1990; 112:423-428
133. Altman R., Rouvier J., Gurfinkel E., et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991; 101:427-431